Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Milton L. Wainberg, MD

Articles by Milton L. Wainberg, MD

Recognizing the pandemic's impact on MSDs can help us increase funding, research, and implementation of MSD treatment.

Challenges and Opportunities Beyond COVID-19

ByMilton L. Wainberg, MD

December 22nd 2021

How can recognizing the pandemic's impact on MSDs help us increase funding, research, and implementation of MSD treatment?

Latest Updated Articles

Challenges and Opportunities Beyond COVID-19
Published: December 22nd 2021 | Updated:

Trending on Psychiatric Times

New Data on Lumateperone for Prevention of Relapse in Schizophrenia

Seltorexant Well-Tolerated in Adolescents as an Adjunct Treatment for Major Depressive Disorder

Asynchronous ADHD Assessment: New Tools for Better Evaluation

Women Are Diagnosed With ADHD 5 Years Later Than Men

Phase 3 Data Support CT-155 as a Novel Digital Therapeutic for Negative Symptoms in Schizophrenia at ECNP

© 2025 MJH Life Sciences^®

All rights reserved.